An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
OBJECTIVES:The objective of this analysis is to perform an indirect comparison of elvitegravir, cobicistat, emtricitabine and tenofovir DF (E/C/F/TDF) to abacavir/lamivudine and dolutegravir (ABC/3TC + DTG) by using 2 trials evaluating each of these regimens in comparison to efavirenz, emtricitabine...
Main Authors: | , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2016-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4872996?pdf=render |
id |
doaj-5675cfcf33db412abc99cc1339a26148 |
---|---|
record_format |
Article |
spelling |
doaj-5675cfcf33db412abc99cc1339a261482020-11-24T21:54:59ZengPublic Library of Science (PLoS)PLoS ONE1932-62032016-01-01115e015540610.1371/journal.pone.0155406An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.Josep M LlibreFrançois RaffiGraeme MoyleGeorg BehrensStephane BoueeGeraldine ReillyPeter BorgDavid PiontkowskyFelipe RogattoOBJECTIVES:The objective of this analysis is to perform an indirect comparison of elvitegravir, cobicistat, emtricitabine and tenofovir DF (E/C/F/TDF) to abacavir/lamivudine and dolutegravir (ABC/3TC + DTG) by using 2 trials evaluating each of these regimens in comparison to efavirenz, emtricitabine and tenofovir DF (EFV/FTC/TDF). METHODS:An indirect comparison was performed by using a generalization of Bucher's methodology to calculate risk differences. Two phase III clinical trials (GS-US-236-0102 and SINGLE-described above) were used. RESULTS:Results of the indirect comparison showed no statistically significant risk difference of the efficacy endpoint of achieving HIV RNA < 50 copies/mL between E/C/F/TDF and ABC/3TC + DTG for the ITT population at weeks 48, 96 and 144: respectively -3.7% (CI95% = [-10.8%; 3.4%]), -5.2% (CI95% = [-13.2%; 2.8%]) and -3.1% (CI95% = [-12.0%; 5.7%]). There was no statistically significant differences in the risk difference for serious adverse events (5.7% (CI95% = [-2.2%; 12.3%])), drug related adverse event (2.7% (CI95% = [-7.0%;12.4%])), drug related serious adverse event (0.8% (CI95% = [-1.6%;3.2%])) and death (0.5% (CI95% = [-0.8%;1.8%])), respectively, between E/C/F/TDF and ABC/3TC + DTG. A significant difference was found for discontinuation due to adverse events with a higher rate for E/C/F/TDF (difference = 8.6% (CI95% = [3.3%; 13.9%])). There was also no statistically significant risk difference of the viral resistance of 1.2% (CI95% = [-1.2; 3.7]) between E/C/F/TDF and ABC/3TC + DTG at week 48, 1.7% at week 96 (CI95% = [-1.1; 4.5]) and 2.2% (CI95% = [-1.0; 5.4]) at week 144.http://europepmc.org/articles/PMC4872996?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Josep M Llibre François Raffi Graeme Moyle Georg Behrens Stephane Bouee Geraldine Reilly Peter Borg David Piontkowsky Felipe Rogatto |
spellingShingle |
Josep M Llibre François Raffi Graeme Moyle Georg Behrens Stephane Bouee Geraldine Reilly Peter Borg David Piontkowsky Felipe Rogatto An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. PLoS ONE |
author_facet |
Josep M Llibre François Raffi Graeme Moyle Georg Behrens Stephane Bouee Geraldine Reilly Peter Borg David Piontkowsky Felipe Rogatto |
author_sort |
Josep M Llibre |
title |
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. |
title_short |
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. |
title_full |
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. |
title_fullStr |
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. |
title_full_unstemmed |
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy. |
title_sort |
indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate and abacavir/lamivudine + dolutegravir in initial therapy. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2016-01-01 |
description |
OBJECTIVES:The objective of this analysis is to perform an indirect comparison of elvitegravir, cobicistat, emtricitabine and tenofovir DF (E/C/F/TDF) to abacavir/lamivudine and dolutegravir (ABC/3TC + DTG) by using 2 trials evaluating each of these regimens in comparison to efavirenz, emtricitabine and tenofovir DF (EFV/FTC/TDF). METHODS:An indirect comparison was performed by using a generalization of Bucher's methodology to calculate risk differences. Two phase III clinical trials (GS-US-236-0102 and SINGLE-described above) were used. RESULTS:Results of the indirect comparison showed no statistically significant risk difference of the efficacy endpoint of achieving HIV RNA < 50 copies/mL between E/C/F/TDF and ABC/3TC + DTG for the ITT population at weeks 48, 96 and 144: respectively -3.7% (CI95% = [-10.8%; 3.4%]), -5.2% (CI95% = [-13.2%; 2.8%]) and -3.1% (CI95% = [-12.0%; 5.7%]). There was no statistically significant differences in the risk difference for serious adverse events (5.7% (CI95% = [-2.2%; 12.3%])), drug related adverse event (2.7% (CI95% = [-7.0%;12.4%])), drug related serious adverse event (0.8% (CI95% = [-1.6%;3.2%])) and death (0.5% (CI95% = [-0.8%;1.8%])), respectively, between E/C/F/TDF and ABC/3TC + DTG. A significant difference was found for discontinuation due to adverse events with a higher rate for E/C/F/TDF (difference = 8.6% (CI95% = [3.3%; 13.9%])). There was also no statistically significant risk difference of the viral resistance of 1.2% (CI95% = [-1.2; 3.7]) between E/C/F/TDF and ABC/3TC + DTG at week 48, 1.7% at week 96 (CI95% = [-1.1; 4.5]) and 2.2% (CI95% = [-1.0; 5.4]) at week 144. |
url |
http://europepmc.org/articles/PMC4872996?pdf=render |
work_keys_str_mv |
AT josepmllibre anindirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT francoisraffi anindirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT graememoyle anindirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT georgbehrens anindirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT stephanebouee anindirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT geraldinereilly anindirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT peterborg anindirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT davidpiontkowsky anindirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT feliperogatto anindirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT josepmllibre indirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT francoisraffi indirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT graememoyle indirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT georgbehrens indirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT stephanebouee indirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT geraldinereilly indirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT peterborg indirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT davidpiontkowsky indirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy AT feliperogatto indirectcomparisonofefficacyandsafetyofelvitegravircobicistatemtricitabinetenofovirdisoproxilfumarateandabacavirlamivudinedolutegravirininitialtherapy |
_version_ |
1725864523925028864 |